Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a genetic trait stop chemotherapy from working? a trial aims to fix that

NCT ID NCT07743086

Disease control Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This trial is testing whether a new dosing algorithm can help people with a genetic trait called Duffy-null get the full benefit of chemotherapy. Many people of African or Middle Eastern descent naturally have lower white blood cell counts (Duffy-null neutropenia), which can lead doctors to reduce or delay chemo doses. The study first develops an algorithm to guide dosing, then tests it in a larger group to see if it keeps treatment on track without increasing risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Standard of care chemotherapy with dose adjustment according to a new algorithm for Duffy-null positive patients
What this could lead to
If successful, this could lead to a personalized chemotherapy dosing approach that helps people with Duffy-null neutropenia receive full, effective doses without increased risk.
What could go wrong
The trial is early (Phase 1/2) and the algorithm is new, so it may not work as hoped. There are also risks from chemotherapy itself, such as infection or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 886 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must self-identify as being of Middle Eastern or African descent. * Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive. * Melanoma is allowed; sarcoma is not eligible. * Secondary malignancies are allowed. * Participants who have received only surgery alone as treatment are eligible * Participant must be between the ages of 18-80. * Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it. Exclusion Criteria: * Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics. • Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion. * Participants who have ever received cytotoxic chemotherapy. • Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion. * Participants who are receiving concurrent chemo-radiation treatment. * Participants who are taking any other investigational drugs. * Participants who are pregnant or breastfeeding. * Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.